Japan Approves Taisho’s Visceral Fat-Reducing Med as Nonprescription Drug

February 20, 2023
Taisho Pharmaceutical said on February 17 that its nonprescription drug containing orlistat has been approved in Japan for the reduction of visceral fat. The agent, known as Alli overseas, will be sold as a “behind-the-counter” med requiring face-to-face guidance by...read more